A case of EGFR mutant lung adenocarcinoma that acquired resistance to EGFR-tyrosine kinase inhibitors with MET amplification and epithelial-to-mesenchymal transition

EGFR mutant lung cancer responds to EGFR tyrosine kinase inhibitors (TKIs), but all patients eventually develop resistance to EGFR-TKIs. Herein we report a case of EGFR mutant lung adenocarcinoma that acquired resistance to EGFR-TKI with MET amplification and epithelial-to-mesenchymal transition (EM...

Descripción completa

Detalles Bibliográficos
Autores principales: Miyoshi, Seigo, Kato, Takahide, Katayama, Hitoshi, Ito, Ryoji, Mizuno, Yosuke, Okura, Takafumi, Higaki, Jitsuo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4399517/
https://www.ncbi.nlm.nih.gov/pubmed/25914548
http://dx.doi.org/10.2147/OTT.S78911

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4399517/
https://www.ncbi.nlm.nih.gov/pubmed/25914548
http://dx.doi.org/10.2147/OTT.S78911

Ejemplares similares